Reducing antibiotic resistance through adequate use of antibiotics

Not Applicable

Completed

• Conditions: Respiratory; Acute respiratory tract infection

• Registration Number: ISRCTN13934505
• Lead Sponsor: Association of Substitute Health Funds e.V. (vdek e.V.)

Brief Summary

2020 protocol in https://pubmed.ncbi.nlm.nih.gov/32996888/ (added 05/10/2020)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2018-12-06
• Study Completion: 2020-03-14
• Last Update Posted: 19 October 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 3000

Inclusion Criteria

Patients:
1. Aged 1 year or older
2. Health insurance with a substitute health fund
3. Physician consultation visit due to ARTI (upper respiratory infection (URTI) and lower respiratory infection (LRTI))
4. Otherwise healthy

Physicians:
1. General practitioners, pediatricians and otorhinolaryngologists
2. Registration with any participating Association of Statutory Health Insurance Physicians” located in Bavaria, Baden-Wuerttemberg, Lower Saxony, North Rhine, Westphalia-Lippe, Brandenburg, Mecklenburg-Western Pomerania and Saarland

Exclusion Criteria

Data of patients who meet at least one of the following criteria:
1. Underlying chronic diseases, which may affect the immune status in any relevant matter (e.g. chronic obstructive pulmonary diseases, cystic fibrosis, immune deficiency of other causes)
2. Pregnancy
3. Other relevant infectious diseases e.g. urinary tract infections

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Physicians' overall annual antibiotic prescription rate (regardless of the diagnosis), for all patients insured with a substitute health fund before and after the intervention. This is obtained from routine healthcare data from the Central Research Institute of Ambulatory Health Care in Germany (Zi), assessed using 2016 data (before the intervention), 2017 data and 2018 Q1 data ( available 28/02/2019) and 2018 Q2, Q3 and Q4, and 2019 Q1 data (available 31/12/2019)

Secondary Outcome Measures

Name	Time	Method
<br> 1. Annual antibiotic prescription rate per practice/physician for all patients insured with one of the substitute health funds diagnosed with ARTI before and after the RESIST intervention<br> 2. Quality of antibiotic prescription practice measured by internationally accredited quality indicators (ESAC-Net indicators)<br> 3. A process evaluation, focusing on the practical feasibility of the RESIST program, assessed using:<br> 3.1. Focus group discussions with physicians participating in RESIST between January and July 2017<br> 3.2. Telephone interviews with patients treated by a participating physician due to ARTI between January and July 2017<br>